SUPPLEMENTAL METHODS

THE PROSPER STUDY.
The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomized, double-blind, placebo-controlled trial designed to investigate the effect of pravastatin in prevention of vascular events in older individuals with pre-existing cardiovascular disease or risk factors thereof (1, 2) . Between 15 December 1997 and 7 May 1999, a total of 5,804 individuals were screened at the study centres in Scotland, Ireland and the Netherlands. To be included participants were required to have: (i) either pre-existing vascular disease (coronary, cerebral, or peripheral) or raised risk of such disease because of smoking, hypertension or diabetes; (ii) a plasma total cholesterol level of 4.0-9.0 mmol/L; and (iii) a triglyceride concentration of ≤6.0 mmol/L. The list of exclusion criteria of PROSPER are provided in the design paper (2) and included: (i) poor cognitive function (Mini-Mental State Examination score <24 points); (ii) congestive heart failure (defined as New York Heart Association functional class III or IV); (iii) a diagnosis of atrial fibrillation, or (iv) abnormal laboratory findings such as serum creatinine of >200 μmol/L. For the purpose of the present investigation, we excluded participants with a history of myocardial infarction or stroke (n=980), missing information on hs-cTnT concentration (n=25) or on covariates (n=397), leaving 4,402 participants in the analysis (Online Figure 1) . hs-cTnT concentration was measured in plasma samples obtained six months after randomisation using a high-sensitivity electrochemiluminiscence immunoassay on a Roche Modular Analytics E170 platform. The occurrence of incident outcomes was adjudicated by the PROSPER Endpoints Committee during the in-trial phase (mean duration: 3.2 years) and ascertained with routine health data thereafter. The combined CVD endpoint was composed of fatal coronary heart disease (CHD), non-fatal myocardial infarction, and fatal plus non-fatal stroke (ischemic, hemorrhagic or unclassified). When re-infarction or death occurs following a non-fatal myocardial infarction within the same period of hospitalization (up to and including 14 days from the date of admission), the subsequent event were regarded as the same event unless electrocardiographic and/or post-mortem evidence suggests an infarction in a different site. When death occurred following a non-fatal stroke within a period of 28 days from the event, it was regarded as due to a fatal stroke in the absence of other clinical events. Information on fatal outcomes was available in the overall cohort, whereas additional information on non-fatal outcomes was available for the Scottish trial centre (n=1,889). The institutional ethics review boards of all centres approved the protocol and all participants gave written informed consent. The protocol adhered to the principles of the Declaration of Helsinki.
SUPPLEMENTAL TABLES
Online Table 1 Search strategy for the systematic review of the published literature PubMed ((("high-sensitive" OR "high sensitivity" OR "highly-sensitive" OR "highly sensitivity" OR "sensitive assay") AND troponin OR "sensitive Troponin") AND ("Cardiovascular Diseases" [Mesh] OR "Cardiovascular Disease" OR "Cardiovascular Death" OR "Vascular Disease" OR "Vascular Death" OR "Ischemic Heart Disease" OR "Myocardial ischaemia" OR "Myocardial ischemia" OR "Acute coronary syndrome" OR "Coronary disease" OR "Coronary heart disease" OR "Coronary artery disease" OR "Myocardial infarction" OR "Heart attack" OR "Cerebrovascular disease" OR "Stroke" OR "Apoplexy" OR "Brain vascular accident" OR "Cerebrovascular accident" ) AND ((cohort studies [MeSH] ) OR (epidemiologic studies [MeSH] ) OR (prospective studies [MeSH] ) OR (epidemiologic stud*) OR (cohort stud*) OR (population stud*) OR (prospective stud*) OR (observational stud*) OR (longitudinal stud*) OR (odds OR risk OR hazard)) ) NOT ("Animals"
Web of Science TS=(("high-sensitive" OR "high sensitivity" OR "highly-sensitive" OR "highly sensitivity" OR "sensitive assay") AND troponin OR "sensitive Troponin") AND TS=("Cardiovascular Disease" OR "Cardiovascular Death" OR "Vascular Disease" OR "Vascular Death" OR "Ischemic Heart Disease" OR "Myocardial ischaemia" OR "Myocardial ischemia" OR "Acute coronary syndrome" OR "Coronary disease" OR "Coronary heart disease" OR "Coronary artery disease" OR "Myocardial infarction" OR "Heart attack" OR "Cerebrovascular disease" OR "Stroke" OR "Apoplexy" OR "Brain vascular accident" OR "Cerebrovascular accident" ) AND TS=((epidemiologic stud*) OR (cohort stud*) OR (population stud*) OR (prospective stud*) OR (observational stud*) OR (longitudinal stud*) OR (odds OR risk OR hazard)) EMBASE (("high-sensitive" OR "high sensitivity" OR "highly-sensitive" OR "highly sensitivity" OR "sensitive assay") AND troponin OR "sensitive Troponin").af AND ("Cardiovascular Disease" OR "Cardiovascular Death" OR "Vascular Disease" OR "Vascular Death" OR "Ischemic Heart Disease" OR "Myocardial ischaemia" OR "Myocardial ischemia" OR "Acute coronary syndrome" OR "Coronary disease" OR "Coronary heart disease" OR "Coronary artery disease" OR "Myocardial infarction" OR "Heart attack" OR "Cerebrovascular disease" OR "Stroke" OR "Apoplexy" OR "Brain vascular accident" OR "Cerebrovascular accident" ).af AND ((epidemiologic stud*) OR (cohort stud*) OR (population stud*) OR (prospective stud*) OR (observational stud*) OR (longitudinal stud*) OR (odds OR risk OR hazard)).af Model 1 was adjusted for age, sex, and centre, and stratified by treatment arm. Model 2 was further adjusted for smoking status, history of diabetes mellitus, history of hypertension, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and body mass index. Model 3 was further adjusted for C-reactive protein, estimated glomerular filtration rate, and N-terminal pro B-type natriuretic peptide.
Online
Online .001 *The conventional risk factors model included information on age, sex, centre, smoking status, history of diabetes mellitus, systolic blood pressure, and levels of total cholesterol and high-density lipoprotein cholesterol, and was stratified by treatment arm. Information on hs-cTnT was entered in categories as specified in Figure 1 . †Net reclassification across 10-year risk categories <15%, 15%-<25%, and ≥25%. The models were adjusted for age, sex, centre, smoking status, history of diabetes mellitus, history of hypertension, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and body mass index, and stratified by treatment arm. Abbreviations: BMI=body mass index, CRP=C-reactive protein, eGFR=estimated glomerular filtration rate, HR=hazard ratio, NT-proBNP=N-terminal pro B-type natriuretic peptide. Sizes of data markers indicate the weight of each study in the analysis. For full study names, see footnote to Table 1 .
Online Figure 8 Relative risks for cardiovascular outcomes in individuals in the top vs bottom third of cardiac troponin concentration according to categories of study-level characteristics *P values were calculated from meta-regression. Level of adjustment: +, adjusted for age and sex; ++, adjusted for age, sex, and smoking status; +++, adjusted for age, sex, smoking status, and other established CHD risk factors.
